COSMO PHARMACEUTICALS NV (C43.DE) Fundamental Analysis & Valuation

FRA:C43 • NL0011832936

Current stock price

48.8 EUR
-1.2 (-2.4%)
Last:

This C43.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. C43.DE Profitability Analysis

1.1 Basic Checks

  • C43 had positive earnings in the past year.
  • C43 had a positive operating cash flow in the past year.
  • In multiple years C43 reported negative net income over the last 5 years.
  • C43 had a positive operating cash flow in each of the past 5 years.
C43.DE Yearly Net Income VS EBIT VS OCF VS FCFC43.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • The Return On Assets of C43 (20.60%) is better than 94.23% of its industry peers.
  • With a decent Return On Equity value of 26.74%, C43 is doing good in the industry, outperforming 76.92% of the companies in the same industry.
  • The Return On Invested Capital of C43 (21.60%) is better than 88.46% of its industry peers.
Industry RankSector Rank
ROA 20.6%
ROE 26.74%
ROIC 21.6%
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
C43.DE Yearly ROA, ROE, ROICC43.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20

1.3 Margins

  • The Profit Margin of C43 (49.94%) is better than 98.08% of its industry peers.
  • In the last couple of years the Profit Margin of C43 has grown nicely.
  • Looking at the Operating Margin, with a value of 55.81%, C43 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of C43 has grown nicely.
  • C43 has a better Gross Margin (83.00%) than 86.54% of its industry peers.
  • C43's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 55.81%
PM (TTM) 49.94%
GM 83%
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
C43.DE Yearly Profit, Operating, Gross MarginsC43.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. C43.DE Health Analysis

2.1 Basic Checks

  • C43 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for C43 has been reduced compared to 1 year ago.
  • C43 has more shares outstanding than it did 5 years ago.
  • C43 has a better debt/assets ratio than last year.
C43.DE Yearly Shares OutstandingC43.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
C43.DE Yearly Total Debt VS Total AssetsC43.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 5.80 indicates that C43 is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of C43 (5.80) is better than 90.38% of its industry peers.
  • C43 has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
  • C43 has a Debt to FCF ratio of 0.01. This is amongst the best in the industry. C43 outperforms 98.08% of its industry peers.
  • C43 has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of C43 (0.00) is better than 94.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 5.8
ROIC/WACC2.81
WACC7.68%
C43.DE Yearly LT Debt VS Equity VS FCFC43.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
  • C43 has a Current ratio of 4.19. This is amongst the best in the industry. C43 outperforms 96.15% of its industry peers.
  • C43 has a Quick Ratio of 3.91. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
  • C43 has a Quick ratio of 3.91. This is amongst the best in the industry. C43 outperforms 96.15% of its industry peers.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 3.91
C43.DE Yearly Current Assets VS Current LiabilitesC43.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

9

3. C43.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1315.29% over the past year.
  • The Earnings Per Share has been growing by 85.20% on average over the past years. This is a very strong growth
  • C43 shows a strong growth in Revenue. In the last year, the Revenue has grown by 187.55%.
  • The Revenue has been growing by 33.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%

3.2 Future

  • C43 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.02% yearly.
  • The Revenue is expected to grow by 22.67% on average over the next years. This is a very strong growth
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
C43.DE Yearly Revenue VS EstimatesC43.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
C43.DE Yearly EPS VS EstimatesC43.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

Find the best growth stocksShow best growing peers

8

4. C43.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.98, which indicates a rather cheap valuation of C43.
  • Based on the Price/Earnings ratio, C43 is valued cheaper than 92.31% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of C43 to the average of the S&P500 Index (25.60), we can say C43 is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 8.09, the valuation of C43 can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, C43 is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
  • C43's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.84.
Industry RankSector Rank
PE 5.98
Fwd PE 8.09
C43.DE Price Earnings VS Forward Price EarningsC43.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, C43 is valued cheaply inside the industry as 96.15% of the companies are valued more expensively.
  • 94.23% of the companies in the same industry are more expensive than C43, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 5.46
EV/EBITDA 3.83
C43.DE Per share dataC43.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • C43 has an outstanding profitability rating, which may justify a higher PE ratio.
  • C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. C43.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.85%, C43 has a reasonable but not impressive dividend return.
  • In the last 3 months the price of C43 has falen by -28.24%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 1.95, C43 pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.88, C43 pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.85%

5.2 History

  • The dividend of C43 is nicely growing with an annual growth rate of 7.41%!
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
C43.DE Yearly Dividends per shareC43.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • C43 pays out 24.09% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
C43.DE Yearly Income VS Free CF VS DividendC43.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M
C43.DE Dividend Payout.C43.DE Dividend Payout, showing the Payout Ratio.C43.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

C43.DE Fundamentals: All Metrics, Ratios and Statistics

COSMO PHARMACEUTICALS NV

FRA:C43 (4/29/2025, 7:00:00 PM)

48.8

-1.2 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-06
Earnings (Next)07-23
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.85%
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
Industry RankSector Rank
PE 5.98
Fwd PE 8.09
P/S 3.21
P/FCF 5.46
P/OCF 5.27
P/B 1.72
P/tB 6.01
EV/EBITDA 3.83
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 20.6%
ROE 26.74%
ROCE 24.88%
ROIC 21.6%
ROICexc 28.38%
ROICexgc 129.8%
OM 55.81%
PM (TTM) 49.94%
GM 83%
FCFM 58.76%
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA 0.01
Cap/Depr 46.02%
Cap/Sales 2.12%
Interest Coverage 250
Cash Conversion 100.77%
Profit Quality 117.65%
Current Ratio 4.19
Quick Ratio 3.91
Altman-Z 5.8
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A

COSMO PHARMACEUTICALS NV / C43.DE Fundamental Analysis FAQ

What is the fundamental rating for C43 stock?

ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.


What is the valuation status for C43 stock?

ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.


Can you provide the profitability details for COSMO PHARMACEUTICALS NV?

COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.


What are the PE and PB ratios of COSMO PHARMACEUTICALS NV (C43.DE) stock?

The Price/Earnings (PE) ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 5.98 and the Price/Book (PB) ratio is 1.72.


How financially healthy is COSMO PHARMACEUTICALS NV?

The financial health rating of COSMO PHARMACEUTICALS NV (C43.DE) is 9 / 10.